Karyopharm Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
60.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$4.95next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. XPOVIO Net Product Revenue Quarterly29.2MTarget: 115000000 to 130000000
Total Revenue Quarterly35.1MTarget: 130000000 to 150000000
Combined R&D and SG&A Expenses Quarterly60.5MTarget: 230000000 to 245000000
Watch Items
- Phase 3 XPORT-EC-042 Topline Data in Endometrial CancerTrigger: Statistical significance in the MITT (Modified Intent-to-Treat) PFS populationAction: Evaluate potential for supplemental New Drug Application (sNDA) submission to the FDA
- FDA Engagement and Regulatory Path for Selinexor in MyelofibrosisTrigger: Acceptance of sNDA filing based on Phase 3 SENTRY trial resultsAction: Prepare commercial launch strategy and coordinate potential inclusion in medical compendia
- Cash Runway and Liquidity ManagementTrigger: Cash balance falling below $50 million or runway extending less than 3 monthsAction: Explore strategic collaborations, non-dilutive licensing, or additional capital market transactions
Research as of 19 Jun 2026